Skip to content

Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes

Effect of Pentoxyfilline on Endometrial Thickness and Frozen Embryo Transfer Outcomes

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07499817
Enrollment
100
Registered
2026-03-30
Start date
2023-10-01
Completion date
2026-04-30
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embryo Transfer, IVF, Infertility

Keywords

thawed embryo, IVF

Brief summary

The aim of this work was to investigate the effect of different vasodilators as pentoxifylline in women with unexplained infertility using IVF

Detailed description

A prospective randomized clinical study was carried out on 100 women, aged \<18 to 43 years old, has good quality day five frozen embryos. The study was done after approval from the Ethical Committee Beni Suef University Hospitals, Beni Suef, Egypt. An informed written consent was obtained from the patients. Randomization and blindness: An online randomization program (http://www.randomizer.org ) was used to generate a random list and each patient's code was kept in an opaque sealed envelope. Patients were randomly allocated with 1:1 allocation ratio into two equal groups in a parallel manner: Group 1 (control): received estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D may be increased to two pills T.I.D according to endometrial5 thickness in day 9 measured by vaginal ultrasound. Group 2: received pentoxifylline 400 mg. Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone. All patients were subjected to complete history taking, general examination, laboratory investigations \[Anti-müllerian hormone (AMH), follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E₂), prolactin (PRL) and thyroid-stimulating hormone (TSH)\] and radiological investigations \[Ultrasonography\]. The endometrial thickness was estimated by transvaginal ultrasonography.

Interventions

Once daily in form of (Trental ® Sanofi co.) daily in addition to the above treatment protocol from the first day of the cycle until the day of starting progesterone.

OTHER(control)

estradiol valerate 2 mg. in form of (Cycloprogynova® Bayer Shering Pharma) whitepills starting dose is one pill T.I.D

Sponsors

Beni-Suef University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 43 Years
Healthy volunteers
No

Inclusion criteria

* as good quality day five frozen embryos.

Exclusion criteria

* history of endocrine diseases, * history of any previous surgery that couldm compromise the integrity of endometrium, * cardiovascular, renal and liver diseases,

Design outcomes

Primary

MeasureTime frameDescription
Pregnancy1 monthBeta-Human Chorionic Gonadotropin (β-hCG) was positive

Countries

Egypt

Contacts

CONTACTSara A Salem, MD
sara.abdalla@med.bsu.edu.eg01272842226
PRINCIPAL_INVESTIGATORBeni suef University

Beni-Suef University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026